46 results on '"V.C. Di Maio"'
Search Results
2. Analysis of resistance and phylogenetic clusters in HCV-2c infected patients within the Italian network Vironet C
3. VIRONET-C real life experience of resistance-guided retreatment in HCV infected patients who previously failed a NS5A inhibitor-containing regimen
4. Characterization of baseline factors associated with treatment outcome in HCV-infected patients naive to direct acting antivirals: particular focus on natural resistance
5. Resistance test guided retreatment of HCV infected patients with a previous failure to a NS5A inhibitor-containing regimen: the Italian Vironet C real life experience
6. Inferring the migration routes of hepatitis C virus subtype 1a lineages identifies a need for pan-European prevention strategies
7. On treatment HCV-RNA evaluation in real-life: Still a role in the era of direct acting antiviral agents?
8. Optimal efficacy of interferon-free HCV retreatment after protease inhibitor failure in real life
9. Characterization of resistance profiles in HCV 2-3-4 DAA-naïve and DAA-experienced infected patients in Italy
10. VIROLOGICAL FAILURES TO NEW DIRECT ACTING ANTIVIRALS IN A REAL LIFE SETTING MAY REQUIRE UNCONVENTIONAL REGIMENS FOR RE-TREATMENT
11. In the ERA of New Direct Acting Antiviral Agents HCV Sequencing Allows the Most Accurate Subtype and Genotype Assignment
12. Prevalence and characteristics of resistance associated substitutions in DAA-naive and DAA-failed HCV-3 patients in Italy
13. Multiclass HCV resistance to interferon-free direct acting antivirals regimens in real life failures advocates for tailored second-line therapies
14. The challenge of HCV-retreatment after DAA-failure: real-life experience advocates for caution
15. Multiclass hepatitis C virus resistance to direct acting antivirals in real life interferon-free regimens failures advocates for tailored second-line therapies
16. Early-phase hcv kinetics and role of pre-existing resistance in cirrhotic or interferon-insensitive patients on daclatasvir plus asunaprevir
17. Slow HCV kinetics following Sofosbuvir + Ribavirin administration in real-life setting of liver transplant recipients with severe recurrent hepatitis C
18. Slow achievement of HCV-RNA undetectability in cirrhotic patients treated with sofosbuvir+ribavirin: possible clinical implications in the liver transplant list management
19. Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors
20. Clinical relevance of accurate HCV genotype and subtype assignment by NS3/NS5A/NS5B direct sequencing in the era of new direct acting antiviral agents
21. Presence of resistance associated variants in patients with virological failure to new direct acting antivirals and requirement of unconventional regimens for re-treatment
22. Biphasic Kinetics of HCV-RNA Decay is Accompanied by an even Faster Aminotransferases Normalization in All-Daa Treated Cirrhotic Patients: A Different Scenario from Interferon-Based Therapies
23. P0912 : Early-phase HCV kinetics and role of pre-existing resistance in cirrhotic or interferon-insensitive patients on daclatasvir plus asunaprevir
24. Natural HCV resistance is common in Italy and differently associated to genotypes
25. Daclatasvir/sofosbuvir and ribavirin 800mg flat dose is highly efficacy and safe in genotype 3 compensated and decompensated cirrhotic patients: The CLEO experience
26. HCV resistance test guided retreatments after protease inhibitors failures can induce maximal efficacy rate in real-life
27. The challenge of HCV-retreatment after DAA-failure: Italian real-life from VIRONET-C network
28. P1235 BASELINE/EARLY PRESENCE OF KNOWN AND NOVEL RESISTANCE MUTATIONS IS ASSOCIATED WITH VIRAL FAILURE IN DIFFICULT-TO-TREAT PATIENTS TREATED WITH FIRST GENERATION PROTEASE INHIBITORS
29. P0915 : Clinical relevance of baseline/early detection and persistence of resistant associated variants in HCV-1 patients treated with protease-inhibitors assessed by ultra-deep sequencing
30. P0903 : Slow HCV kinetics following sofosbuvir + ribavirin administration in real-life setting of liver transplant recipients with severe recurrent hepatitis C
31. Does ultra-deep-sequencing in HCV patients treated with boceprevir/telaprevir-based therapy provide an added value in comparison to standard population-sequencing in the detection of resistance?
32. T-09 Correlation between NS5A variants and fibrosis progression in patients with HCV recurrence after liver transplantation
33. OC-24 Genotype analysis, at baseline and early time-points, by population and ultra-deep sequencing in HCV patients treated with BOC/TVR-based therapy
34. 503 NOVEL REVERSE TRANSCRIPTASE MUTATIONS SPECIFICALLY ASSOCIATED WITH SELECTED ANTI-HBV TREATMENT CAN INDUCE ALTERATIONS AND STOP-CODONS IN HBV S ANTIGEN
35. 487 KEY PATTERNS OF HBX AND PRE-S1/S2 MUTATIONS ARE INVOLVED IN MECHANISMS UNDERLYING HBV-INDUCED HEPATOCELLULAR CARCINOMA IN VIVO
36. Clinical relevance of next generation sequencing on baseline detection of minority resistance associated variants in HCV-1 patients treated with protease inhibitors
37. P1236 NS3, NS5A AND NS5B COEVOLUTION DURING TREATMENT WITH FIRST-GENERATION PROTEASE INHIBITORS
38. Early viral dynamics in HCV-RNA decay and NS3-resistance development predict the risk of failure to first-generation protease inhibitors
39. Key genetic markers in the full-length HBsAg gene correlate with HBV-driven carcinogenesis by affecting HBsAg secretion and release
40. 12 HCV KINETICS AND QUASISPECIES EVOLUTION WITHIN THE FIRST HOURS OF TELAPREVIR-BASED TRIPLE THERAPY IN PREVIOUSLY TREATED HCV-PATIENTS
41. 63 CORRELATION OF EARLY DETECTION OF HCV NS3-RESISTANCE AND VIROLOGICAL FAILURE IN PATIENTS TREATED WITH TRIPLE THERAPY INCLUDING TELAPREVIR OR BOCEPREVIR
42. 430 KEY GENETIC SIGNATURES IN THE WHOLE pre-S1/Pre-S2/S GENE CORRELATE WITH HBV-INDUCED CARCINOGENESIS BY AFFECTING HBsAg SECRETION AND RELEASE
43. 166 HCV DIVERSITY AND FIBROSIS PROGRESSION: NS5A AND CORE VARIANTS CORRELATE WITH SEVERITY OF HCV RECURRENCE AFTER LIVER TRANSPLANTATION
44. OC.03.1 EARLY DYNAMIC EVALUATION OF THE NS3 HCV-GENOME REGION DURING TRIPLE THERAPY INCLUDING TELAPREVIR OR BOCEPREVIR IN PATIENTS WITH CHRONIC HEPATITIS C, GENOTYPE 1: PRELIMINARY RESULTS FROM THE SCANNER STUDY
45. P.11.22 HCV GENOME VARIANTS CORRELATE WITH SEVERITY OF HCV RECURRENCE AFTER LIVER TRANSPLANTATION: DOES THE VIRAL DIVERSITY PLAY A ROLE ON FIBROSIS PROGRESSION?
46. F-01 Baseline and early dynamic evaluation of HCV NS3-resistance
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.